Document is current
Any future updates will be listed below
-
Authors
Roh, Heejin https://orcid.org/0000-0001-5100-689X
Shen, Simon P. https://orcid.org/0000-0003-2310-7831
Hu, Yan
Kwok, Hui Si
Siegenfeld, Allison P. https://orcid.org/0000-0001-8599-577X
Lee, Ceejay
Zepeda, Marcanthony U.
Guo, Chun-Jie https://orcid.org/0009-0001-7421-586X
Roseman, Shelby A.
Comenho, Caroline https://orcid.org/0000-0003-2955-1984
Sankaran, Vijay G. https://orcid.org/0000-0003-0044-443X
Buenrostro, Jason D. https://orcid.org/0000-0001-9958-3987
Liau, Brian B. https://orcid.org/0000-0002-2985-462X
-
Funding
Funding for this research was provided by:
Broad Institute
Camille and Henry Dreyfus Foundation
Alfred P. Sloan Foundation
Harvard University
U.S. Department of Health & Human Services | National Institutes of Health (R35GM153476, F31HL174076, R01DK103794)
National Science Foundation (DGE1745303)
Sara Elizabeth O'Brien Trust
Simeon J. Fortin Charitable Foundation
Bank of America
Howard Hughes Medical Institute
- License Information
-
More Information
Article History
Received: 10 January 2025
Accepted: 3 August 2025
First Online: 11 September 2025
Competing interests
: B.B.L. is a cofounder, member of the scientific advisory board and holds equity in Light Horse Therapeutics, and receives financial support from Ono Pharmaceuticals. J.D.B. is on the scientific advisory board for Camp4 and seqWell and is a consultant at the Treehouse Family Foundation. V.G.S. is an advisor for Ensoma. H.R., S.P.S., Y.H. and B.B.L. are co-inventors on a U.S. provisional patent application 63/734,670 regarding technologies described in this paper. The other authors declare no competing interests.
